Boundless Bio Inc. (BOLD) Price & Analysis

Compare

33 Followers

BOLD Stock Chart & Stats

$1.32

-$0.03(-1.15%)

At close: Jan 08 4:00 PM EST

$1.32

-$0.03(-1.15%)

Day’s Range― - ―

52-Week Range$1.00 - $3.75

Previous CloseN/A

Volume5.57K

Average Volume (3M)116.50K

Market Cap

$28.43M

Enterprise Value-$55.06M

Total Cash (Recent Filing)$127.15M

Total Debt (Recent Filing)$49.51M

Price to Earnings (P/E)―

Beta1.83

Next Earnings

Nov 06, 2025

EPS Estimate

-0.58

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.70

Shares Outstanding22,385,610

10 Day Avg. Volume161,825

30 Day Avg. Volume116,496

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-1.94

Enterprise Value/Revenue-52.14

Enterprise Value/Gross Profit149.62

Enterprise Value/Ebitda0.90

Forecast

1Y Price Target

$3.50

Price Target Upside165.15% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe BBI-355 + BBI-825 combination trial is now open for enrollment, with proof-of-concept expected within the current cash runway.

Financial StabilityThe current cash position supports operations into the first half of 2028, providing downside protection and a risk-mitigating feature.

InnovationEcDNA-directed therapies could represent a breakthrough for drug-resistant tumors, with BBI-355 + BBI-825 offering a rational dual-node inhibition approach.

Bears Say

Stock ValuationThe company reported a reduction in price target from $5 to $4 per share.

Boundless Bio Inc. News

Hold Rating on Boundless Bio Inc.: Awaiting Clinical Validation of Innovative Therapies

In a report released yesterday, Andrew Berens from Leerink Partners maintained a Hold rating on Boundless Bio Inc.,...

2M ago

BOLD

Boundless Bio price target lowered to $4 from $5 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Boundless Bio (BOLD) to $4 from $5 and keeps a...

2M ago

BOLD

Boundless Bio Reports Q2 2025 Financial Results

Boundless Bio Inc. ( ($BOLD) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

BOLD

Boundless Bio reports Q2 EPS (70c), consensus (65c)

“We are executing with sharpened focus on programs that we believe have the strongest scientific rationale and greatest...

2M ago

BOLD

Boundless Bio initiated with Early-Stage Biotech at Goldman Sachs

Goldman Sachs analyst Richard Law initiated coverage of Boundless Bio (BOLD) with an Early-Stage Biotech rating, saying the...

3M ago

BOLD

Boundless Bio Elects Directors and Ratifies Auditor

Boundless Bio Inc. ( ($BOLD) ) just unveiled an update. At the annual meeting of stockholders held on...

4M ago

BOLD

Boundless Bio initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Boundless Bio (BOLD) with a Buy rating and $5 price target Boundless is...

5M ago

BOLD

Boundless Bio Inc. Reports Q1 2025 Financial Results

Boundless Bio Inc. ( ($BOLD) ) has released its Q1 earnings. Here is a breakdown of the information...

5M ago

BOLD

Hold Rating Issued for Boundless Bio Inc. Amid Strategic Setbacks and Delayed Program Validations

In a report released today, Andrew Berens from Leerink Partners downgraded Boundless Bio Inc. (BOLD – Research Report)...

5M ago

BOLD

Boundless Bio downgraded to Market Perform from Outperform at Leerink

Leerink downgraded Boundless Bio (BOLD) to Market Perform from Outperform with a price target of $3, down from...

5M ago

BOLD

Boundless Bio Announces Major Workforce Reduction Strategy

Boundless Bio Inc. ( ($BOLD) ) has shared an update. On May 23, 2025, Boundless Bio announced a...

5M ago

BOLD

Boundless Bio discontinuing BBI-355 and BBI-825 programs

Boundless Bio (BOLD) “provided business updates focused on optimizing the Company’s portfolio for patient impact and long-term value-creation....

5M ago

BOLD

Positive Outlook for Boundless Bio Inc. Driven by Promising Pipeline Developments and Strong Financial Position

Analyst Andrew Berens of Leerink Partners maintained a Buy rating on Boundless Bio Inc. (BOLD – Research Report),...

5M ago

BOLD

Boundless Bio reports Q1 EPS (71c) vs ($12.27) last year

“Boundless remains committed to delivering new therapeutic options to patients with high unmet need oncogene amplified cancers,” said...

5M ago

BOLD

BOLD FAQ

What was Boundless Bio Inc.’s price range in the past 12 months?

Boundless Bio Inc. lowest stock price was $1.00 and its highest was $3.75 in the past 12 months.

What is Boundless Bio Inc.’s market cap?

Boundless Bio Inc.’s market cap is $28.43M.

When is Boundless Bio Inc.’s upcoming earnings report date?

Boundless Bio Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 21 days.

How were Boundless Bio Inc.’s earnings last quarter?

Boundless Bio Inc. released its earnings results on Aug 05, 2025. The company reported -$0.7 earnings per share for the quarter, missing the consensus estimate of -$0.65 by -$0.05.

Is Boundless Bio Inc. overvalued?

According to Wall Street analysts Boundless Bio Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Boundless Bio Inc. pay dividends?

Boundless Bio Inc. does not currently pay dividends.

What is Boundless Bio Inc.’s EPS estimate?

Boundless Bio Inc.’s EPS estimate is -0.58.

How many shares outstanding does Boundless Bio Inc. have?

Boundless Bio Inc. has 22,385,610 shares outstanding.

What happened to Boundless Bio Inc.’s price movement after its last earnings report?

Boundless Bio Inc. reported an EPS of -$0.7 in its last earnings report, missing expectations of -$0.65. Following the earnings report the stock price went down -1.667%.

Which hedge fund is a major shareholder of Boundless Bio Inc.?

Currently, no hedge funds are holding shares in BOLD

Boundless Bio Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-42.65%

Trailing 12-Months

Asset Growth

-4.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Boundless Bio Inc.

Boundless Bio Inc. (BOLD) is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in targeting extrachromosomal DNA (ecDNA) in cancer cells, aiming to address genomic amplification and improve treatment outcomes. Boundless Bio operates within the biopharmaceutical sector, leveraging cutting-edge research to create products that can potentially transform cancer care.

Boundless Bio Inc. (BOLD) Earnings & Revenues

Historic Earnings Reports

BOLD Stock 12 Month Forecast

Average Price Target

$3.50

▲(165.15% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","14":"$14","3.5":"$3.5","10.5":"$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.3784615384615384,1.596923076923077,1.8153846153846152,2.0338461538461536,2.252307692307692,2.4707692307692306,2.689230769230769,2.9076923076923076,3.126153846153846,3.344615384615384,3.563076923076923,3.781538461538461,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.3399999999999999,1.52,1.7,1.88,2.0599999999999996,2.24,2.42,2.5999999999999996,2.78,2.96,3.1399999999999997,3.3200000000000003,{"y":3.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.16,1.3015384615384615,1.443076923076923,1.5846153846153845,1.7261538461538461,1.8676923076923078,2.0092307692307694,2.1507692307692308,2.292307692307692,2.433846153846154,2.575384615384616,2.716923076923077,2.8584615384615386,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.54,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.41,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.61,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >